Reports from a U.S. passive surveillance system identified no unexpected safety events following immunization with the mpox JYNNEOS vaccine.
In response to the mpox outbreak in 2022, CDC recommended vaccination with the JYNNEOS vaccine for people at high risk for infection. JYNNEOS contains an attenuated, nonreplicating orthopoxvirus and was approved by the FDA in 2019 for prevention of smallpox and mpox disease in adults aged ≥18 (see NEJM JW Infect Dis Jun 8 2023). This vaccine is effective at substantially reducing risk for hospitalization among persons with mpox, including those with HIV (NEJM JW Infect Dis Sep 19 2023). To monitor post-licensure vaccine safety, the Vaccine Adverse Event Reporting system (VAERS; a passive surveillance system) and V-safe (a voluntary smartphone-based system) were utilized.
Between May 2022 and March 2023, a total of 1,207,056 JYNNEOS vaccine d…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)